<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604291</url>
  </required_header>
  <id_info>
    <org_study_id>ML28268</org_study_id>
    <nct_id>NCT01604291</nct_id>
  </id_info>
  <brief_title>An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C</brief_title>
  <official_title>Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clalit Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multi-center, observational study will evaluate the efficacy and safety of dual and
      triple therapies based on Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis
      C. Patients receiving treatment with either Pegasys plus ribavirin or Pegasys plus ribavirin
      plus telaprevir/boceprevir will be observed for the duration of their treatment and for up to
      24 weeks of follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 28, 2012</start_date>
  <completion_date type="Actual">February 10, 2016</completion_date>
  <primary_completion_date type="Actual">February 10, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Viral Response (SVR) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels &lt; 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of SVR at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>SVR at Week 24 is compared by treatment group, type of infection, prior treatments and genotype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With SVR at Week 24 According to the Demographic Characteristics</measure>
    <time_frame>Week 24</time_frame>
    <description>The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels &lt; 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion. Number of participants analysed signifies participants who were evaluated for outcome measure. Data for this outcome measure was not summarized for each arm. Hence, data is reported for all participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>RVR was defined as HCV-RNA &lt;50 IU/mL by Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Extended RVR</measure>
    <time_frame>Week 4 and 12 for telaprevir group; Week 8 and 24 for boceprevir group</time_frame>
    <description>Extended RVR was defined as HCV-RNA &lt;50 IU/mL at weeks 4 and 12 for participants treated with telaprevir; or at weeks 8 &amp; 24 for participants treated with boceprevir.
The assessment was performed in participants who received triple therapy in treatment arms 'Peginterferon Alfa-2a + Ribavirin +Telaprevir' and 'Peginterferon Alfa-2a + Ribavirin + Boceprevir'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</measure>
    <time_frame>Week 12</time_frame>
    <description>Complete early virologic response (cEVR) was defined as HCV-RNA &lt;50 IU/mL by Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With End of Treatment Response (EoT)</measure>
    <time_frame>Week 24</time_frame>
    <description>End-of-Treatment (EoT) response was defined as HCV-RNA &lt;50 IU/mL by the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Relapse</measure>
    <time_frame>Week 72</time_frame>
    <description>Virologic relapse was defined as detectable HCV-RNA during the treatment-free follow-up period in participants with HCV-RNA &lt;50 IU/mL at EoT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Duration</measure>
    <time_frame>Week 48</time_frame>
    <description>The average amount of time a treatment was prescribed to participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose Modification of Peginterferon Alfa-2a</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose Modification of Ribavirin</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose Modification of Telaprevir/Boceprevir</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Week 48</time_frame>
    <description>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Safety analysis included 2 additional participants in arm 'Peginterferon Alfa-2a + Ribavirin + Telaprevir'. The safety parameters were analyzed by the treatment actually received by the participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Value of Hemoglobin in Participants With Treatment-Induced Anemia</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Regimen for HCV Treatment Induced Anemia</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had SVR at Week 24 With Dose Modifications</measure>
    <time_frame>Week 24</time_frame>
    <description>Participants with dose modifications who had achieved SVR at Week 24 were reported. Data was collected for all participants who had dose modification of Peginterferon alfa-2a, Ribavirin or Telaprevir/boceprevir in any of the treatment regimen during the study.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">991</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis C patients initiating Pegasys-based treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Chronic hepatitis C (all genotypes, naïve or treatment experienced, HCV mono-infected
             or HCV-HIV co-infected)

          -  Receiving either dual therapy (Pegasys plus ribavirin) or triple therapy (Pegasys plus
             ribavirin plus telaprevir/boceprevir)

          -  No contra-indications to Pegasys and ribavirin therapy or to treatment regimen
             containing protease inhibitor (telaprevir or boceprevir) as detailed in local
             Prescribing Information

          -  Quantitative serum HCV RNA by PCR test before initiation of treatment

        Exclusion Criteria:

          -  Hepatitis A/B co-infection

          -  Evidence of severe illness, active malignancy, or any other conditions which would
             make the patient, in the opinion of the investigator, unsuitable for the study

          -  Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haemek Hospital; Gastroenterology</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai MC; Gastroenterology</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center; Gastroenterology</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84105</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Hospital; Gastroenterology</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center; Gastroenterology - Liver Unit</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnei-Zion Medical Center; Gastroenterology</name>
      <address>
        <city>Haifa</city>
        <zip>33394</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Hospital; Liver Unit</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Hospital; Gastroenterology Unit</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Hospital Liver Unit; Liver Unit</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Hospital; Liver Unit</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center; Liver Unit</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Galilee Hospital - Nahariya</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family Medical Center; Liver Unit</name>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasharon Mc; Gastroenterology</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beilinson-Rabin Liver Unit; Liver Unit</name>
      <address>
        <city>Petah Tiqwa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center; Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center; Gastroenterology Unit</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rebecca Sieff Medical Center; Liver Unit</name>
      <address>
        <city>Safed</city>
        <zip>13110</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center; Liver Unit</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poria Hospital; Gastroenterology</name>
      <address>
        <city>Tiberias</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh; Gastroenterology</name>
      <address>
        <city>Zerifin</city>
        <zip>6093000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 21, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2012</study_first_posted>
  <results_first_submitted>July 5, 2017</results_first_submitted>
  <results_first_submitted_qc>November 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 14, 2019</results_first_posted>
  <last_update_submitted>November 21, 2018</last_update_submitted>
  <last_update_submitted_qc>November 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 21 investigational centers in Israel.</recruitment_details>
      <pre_assignment_details>The study was consisted of 3 arms of treatments: 1. Dual therapy: Peginterferon alfa-2a &amp; Ribavirin; 2. Triple therapy :Peginterferon alfa 2a &amp; Ribavirin &amp; Telaprevir; 3. Triple therapy: Peginterferon alfa 2a &amp; Ribavirin &amp; Boceprevir</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peginterferon Alfa-2a + Ribavirin</title>
          <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
        </group>
        <group group_id="P2">
          <title>Peginterferon Alfa-2a + Ribavirin + Telaprevir</title>
          <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Teleprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
        </group>
        <group group_id="P3">
          <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
          <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
        </group>
        <group group_id="P4">
          <title>No Information on Treatment Allocation</title>
          <description>Participants for which Treatment Allocation Data is Unavailable.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="443"/>
                <participants group_id="P3" count="193"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="443"/>
                <participants group_id="P3" count="193"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Enrolled Participants</population>
      <group_list>
        <group group_id="B1">
          <title>Peginterferon Alfa-2a + Ribavirin</title>
          <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
        </group>
        <group group_id="B2">
          <title>Peginterferon Alfa-2a + Ribavirin + Telaprevir</title>
          <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Teleprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
        </group>
        <group group_id="B3">
          <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
          <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
        </group>
        <group group_id="B4">
          <title>No Information on Treatment Allocation</title>
          <description>Participants for which Treatment Allocation Data is Unavailable</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="311"/>
            <count group_id="B2" value="443"/>
            <count group_id="B3" value="193"/>
            <count group_id="B4" value="44"/>
            <count group_id="B5" value="991"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.1" spread="10.6"/>
                    <measurement group_id="B2" value="50.3" spread="11.0"/>
                    <measurement group_id="B3" value="51.1" spread="11.6"/>
                    <measurement group_id="B4" value="48.1" spread="12.0"/>
                    <measurement group_id="B5" value="48.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="282"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Viral Response (SVR) at Week 24</title>
        <description>The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels &lt; 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.</description>
        <time_frame>Week 24</time_frame>
        <population>Modified All Treated (mTRT) Population: includes all participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; the participants' treatment documentation was sufficient for assignment to treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin + Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Viral Response (SVR) at Week 24</title>
          <description>The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels &lt; 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.</description>
          <population>Modified All Treated (mTRT) Population: includes all participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; the participants' treatment documentation was sufficient for assignment to treatment groups.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="442"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" lower_limit="81.1" upper_limit="91.9"/>
                    <measurement group_id="O2" value="94.8" lower_limit="91.6" upper_limit="97.1"/>
                    <measurement group_id="O3" value="85.2" lower_limit="77.4" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of SVR at Week 24</title>
        <description>SVR at Week 24 is compared by treatment group, type of infection, prior treatments and genotype.</description>
        <time_frame>Week 24</time_frame>
        <population>Modified All Treated (mTRT) Population: includes all participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; the participants' treatment documentation was sufficient for assignment to treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin + Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of SVR at Week 24</title>
          <description>SVR at Week 24 is compared by treatment group, type of infection, prior treatments and genotype.</description>
          <population>Modified All Treated (mTRT) Population: includes all participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; the participants' treatment documentation was sufficient for assignment to treatment groups.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="442"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HCV Mono Infection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6" lower_limit="80.3" upper_limit="91.5"/>
                    <measurement group_id="O2" value="94.8" lower_limit="91.5" upper_limit="97.0"/>
                    <measurement group_id="O3" value="84.5" lower_limit="77.2" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV/HCV Co-Infection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="NA" upper_limit="NA">100% of participants with HIV/HCV co-infection had a SVR-24 response.</measurement>
                    <measurement group_id="O2" value="100" lower_limit="NA" upper_limit="NA">100% of participants with HIV/HCV co-infection had a SVR-24 response.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" lower_limit="68.0" upper_limit="93.8"/>
                    <measurement group_id="O2" value="94.9" lower_limit="91.6" upper_limit="97.1"/>
                    <measurement group_id="O3" value="84.4" lower_limit="77.2" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Genotypes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2" lower_limit="81.3" upper_limit="93.2"/>
                    <measurement group_id="O2" value="100" lower_limit="NA" upper_limit="NA">100% of participants in this arm with other genotypes had a SVR rate.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment - Naive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="83.6" upper_limit="94.1"/>
                    <measurement group_id="O2" value="95.5" lower_limit="89.5" upper_limit="98.5"/>
                    <measurement group_id="O3" value="86.7" lower_limit="73.2" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment - Experienced</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="182"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                    <measurement group_id="O2" value="94.5" lower_limit="90.1" upper_limit="97.3"/>
                    <measurement group_id="O3" value="83.1" lower_limit="73.6" upper_limit="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With SVR at Week 24 According to the Demographic Characteristics</title>
        <description>The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels &lt; 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion. Number of participants analysed signifies participants who were evaluated for outcome measure. Data for this outcome measure was not summarized for each arm. Hence, data is reported for all participants.</description>
        <time_frame>Week 24</time_frame>
        <population>Participants who treated for chronic hepatitis C(CHC)with either dual therapy (peginterferon alfa-2a and ribavirin)or triple therapy(peginterferon alfa-2a and ribavirin and telaprevir/boceprevir)for up to 24 weeks thereafter in line with local prescribing information at time of study and for whom demographic baseline characteristics were available.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants who had dual or triple therapy as part of their drug regimen at the discretion of the investigator in accordance with the local prescribing information at the time of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With SVR at Week 24 According to the Demographic Characteristics</title>
          <description>The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels &lt; 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion. Number of participants analysed signifies participants who were evaluated for outcome measure. Data for this outcome measure was not summarized for each arm. Hence, data is reported for all participants.</description>
          <population>Participants who treated for chronic hepatitis C(CHC)with either dual therapy (peginterferon alfa-2a and ribavirin)or triple therapy(peginterferon alfa-2a and ribavirin and telaprevir/boceprevir)for up to 24 weeks thereafter in line with local prescribing information at time of study and for whom demographic baseline characteristics were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gender: Male - Achieved SVR 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender: Male - Did not achieve SVR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender: Female - Achieved SVR 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender: Female - Did not achieve SVR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age - Achieved SVR 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age - Did not achieve SVR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Height - Achieved SVR 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Height - Did not achieve SVR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight - Achieved SVR 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight - Did not achieve SVR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Mass Index - Achieved SVR 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Mass Index - Did not achieve SVR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Correlation between SVR 24 and Gender</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9109</p_value>
            <p_value_desc>The p-value from chi-square is the difference between SVR achieved (yes/no) and dose modifications.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Correlation between SVR 24 and Age</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1163</p_value>
            <p_value_desc>A t-test was done to compare SVR participants to non-SVR.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Correlation between SVR 24 and Height</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9269</p_value>
            <p_value_desc>A t-test was done to compare SVR participants to non-SVR.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Correlation between SVR 24 and Weight</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3376</p_value>
            <p_value_desc>A t-test was done to compare SVR participants to non-SVR.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Correlation between SVR 24 and Body mass index.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4618</p_value>
            <p_value_desc>A t-test was done to compare SVR participants to non-SVR.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</title>
        <description>RVR was defined as HCV-RNA &lt;50 IU/mL by Week 4</description>
        <time_frame>Week 4</time_frame>
        <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribvavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin +Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</title>
          <description>RVR was defined as HCV-RNA &lt;50 IU/mL by Week 4</description>
          <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" lower_limit="54.4" upper_limit="67.6"/>
                    <measurement group_id="O2" value="70.9" lower_limit="66.1" upper_limit="75.3"/>
                    <measurement group_id="O3" value="21.1" lower_limit="15.0" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Extended RVR</title>
        <description>Extended RVR was defined as HCV-RNA &lt;50 IU/mL at weeks 4 and 12 for participants treated with telaprevir; or at weeks 8 &amp; 24 for participants treated with boceprevir.
The assessment was performed in participants who received triple therapy in treatment arms 'Peginterferon Alfa-2a + Ribavirin +Telaprevir' and 'Peginterferon Alfa-2a + Ribavirin + Boceprevir'.</description>
        <time_frame>Week 4 and 12 for telaprevir group; Week 8 and 24 for boceprevir group</time_frame>
        <population>mTRT population:participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy;had received one of study's triple combination therapies;participants' treatment documentation was sufficient for assignment to treatment groups.Number of participants analyzed:participants evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribavirin +Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Extended RVR</title>
          <description>Extended RVR was defined as HCV-RNA &lt;50 IU/mL at weeks 4 and 12 for participants treated with telaprevir; or at weeks 8 &amp; 24 for participants treated with boceprevir.
The assessment was performed in participants who received triple therapy in treatment arms 'Peginterferon Alfa-2a + Ribavirin +Telaprevir' and 'Peginterferon Alfa-2a + Ribavirin + Boceprevir'.</description>
          <population>mTRT population:participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy;had received one of study's triple combination therapies;participants' treatment documentation was sufficient for assignment to treatment groups.Number of participants analyzed:participants evaluated for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="67.7" upper_limit="77.2"/>
                    <measurement group_id="O2" value="70.7" lower_limit="60.7" upper_limit="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Early Virologic Response (cEVR)</title>
        <description>Complete early virologic response (cEVR) was defined as HCV-RNA &lt;50 IU/mL by Week 12</description>
        <time_frame>Week 12</time_frame>
        <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribvavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin +Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Early Virologic Response (cEVR)</title>
          <description>Complete early virologic response (cEVR) was defined as HCV-RNA &lt;50 IU/mL by Week 12</description>
          <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="372"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="68.3" upper_limit="81.0"/>
                    <measurement group_id="O2" value="84.9" lower_limit="80.9" upper_limit="88.4"/>
                    <measurement group_id="O3" value="62.0" lower_limit="54.0" upper_limit="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With End of Treatment Response (EoT)</title>
        <description>End-of-Treatment (EoT) response was defined as HCV-RNA &lt;50 IU/mL by the end of treatment.</description>
        <time_frame>Week 24</time_frame>
        <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribvavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin +Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With End of Treatment Response (EoT)</title>
          <description>End-of-Treatment (EoT) response was defined as HCV-RNA &lt;50 IU/mL by the end of treatment.</description>
          <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="430"/>
                <count group_id="O3" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="81.8" upper_limit="90.1"/>
                    <measurement group_id="O2" value="81.9" lower_limit="77.9" upper_limit="85.4"/>
                    <measurement group_id="O3" value="76.6" lower_limit="69.9" upper_limit="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Relapse</title>
        <description>Virologic relapse was defined as detectable HCV-RNA during the treatment-free follow-up period in participants with HCV-RNA &lt;50 IU/mL at EoT.</description>
        <time_frame>Week 72</time_frame>
        <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribvavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin +Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Relapse</title>
          <description>Virologic relapse was defined as detectable HCV-RNA during the treatment-free follow-up period in participants with HCV-RNA &lt;50 IU/mL at EoT.</description>
          <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="431"/>
                <count group_id="O3" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="NA">No participants in this arm suffered a virologic relapse.</measurement>
                    <measurement group_id="O3" value="0" lower_limit="NA" upper_limit="NA">No participants in this arm suffered a virologic relapse.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Duration</title>
        <description>The average amount of time a treatment was prescribed to participants.</description>
        <time_frame>Week 48</time_frame>
        <population>All Enrolled Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin + Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Duration</title>
          <description>The average amount of time a treatment was prescribed to participants.</description>
          <population>All Enrolled Participants</population>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="443"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peginterferon Alfa-2a Treatment Duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="11.5"/>
                    <measurement group_id="O2" value="34.8" spread="15.2"/>
                    <measurement group_id="O3" value="36.1" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ribavirin Treatment Duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="11.6"/>
                    <measurement group_id="O2" value="34.8" spread="15.2"/>
                    <measurement group_id="O3" value="36.1" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telaprevir/ Boceprevir Treatment Duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Participants in this arm did not receive Telaprevir or Boceprevir</measurement>
                    <measurement group_id="O2" value="11.8" spread="4.6"/>
                    <measurement group_id="O3" value="30.6" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Dose Modification of Peginterferon Alfa-2a</title>
        <time_frame>Week 48</time_frame>
        <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin +Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Dose Modification of Peginterferon Alfa-2a</title>
          <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="421"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.5" spread="9.7"/>
                    <measurement group_id="O2" value="247.6" spread="4.1"/>
                    <measurement group_id="O3" value="328.4" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Dose Modification of Ribavirin</title>
        <time_frame>Week 48</time_frame>
        <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribvavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin +Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Dose Modification of Ribavirin</title>
          <population>mTRT population: participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; participants' treatment documentation was sufficient for assignment to treatment groups. Number of participants analyzed: participants evaluated for this outcome measure.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">No participants in this arm had their Ribavirin dose modified.</measurement>
                    <measurement group_id="O2" value="61.4" spread="3.6"/>
                    <measurement group_id="O3" value="89.4" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Dose Modification of Telaprevir/Boceprevir</title>
        <time_frame>Week 48</time_frame>
        <population>mTRT population:participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy;had received 1 of study's triple combination therapies;participants' treatment documentation was sufficient for assignment to treatment groups.Number of participants analyzed:participants evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribavirin +Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Dose Modification of Telaprevir/Boceprevir</title>
          <population>mTRT population:participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy;had received 1 of study's triple combination therapies;participants' treatment documentation was sufficient for assignment to treatment groups.Number of participants analyzed:participants evaluated for this outcome measure.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.6" spread="0.7"/>
                    <measurement group_id="O2" value="82.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <description>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Safety analysis included 2 additional participants in arm 'Peginterferon Alfa-2a + Ribavirin + Telaprevir'. The safety parameters were analyzed by the treatment actually received by the participants.</description>
        <time_frame>Week 48</time_frame>
        <population>Safety Population. Included only participants who had received at least one dose of peginterferon alfa-2a plus ribavirin or peginterferon alfa-2a plus ribavirin plus telaprevir/boceprevir and had at least one post-baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin + Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)</title>
          <description>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Safety analysis included 2 additional participants in arm 'Peginterferon Alfa-2a + Ribavirin + Telaprevir'. The safety parameters were analyzed by the treatment actually received by the participants.</description>
          <population>Safety Population. Included only participants who had received at least one dose of peginterferon alfa-2a plus ribavirin or peginterferon alfa-2a plus ribavirin plus telaprevir/boceprevir and had at least one post-baseline safety assessment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="445"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="79.3"/>
                    <measurement group_id="O3" value="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Value of Hemoglobin in Participants With Treatment-Induced Anemia</title>
        <time_frame>Week 48</time_frame>
        <population>Safety Population. Included only participants who had received at least one dose of peginterferon alfa-2a plus ribavirin or peginterferon alfa-2a plus ribavirin plus telaprevir/boceprevir and had at least one post-baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin + Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a +Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Value of Hemoglobin in Participants With Treatment-Induced Anemia</title>
          <population>Safety Population. Included only participants who had received at least one dose of peginterferon alfa-2a plus ribavirin or peginterferon alfa-2a plus ribavirin plus telaprevir/boceprevir and had at least one post-baseline safety assessment.</population>
          <units>Grams per Deciliter (g/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="1.6"/>
                    <measurement group_id="O2" value="9.2" spread="1.3"/>
                    <measurement group_id="O3" value="9.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment Regimen for HCV Treatment Induced Anemia</title>
        <time_frame>Week 48</time_frame>
        <population>Safety Population. Included only participants who had received at least one dose of peginterferon alfa-2a plus ribavirin or peginterferon alfa-2a plus ribavirin plus telaprevir/boceprevir and had at least one post-baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a + Ribvavirin</title>
            <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a + Ribavirin +Telaprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Telaprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
            <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Regimen for HCV Treatment Induced Anemia</title>
          <population>Safety Population. Included only participants who had received at least one dose of peginterferon alfa-2a plus ribavirin or peginterferon alfa-2a plus ribavirin plus telaprevir/boceprevir and had at least one post-baseline safety assessment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RVB Dose Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="56.5"/>
                    <measurement group_id="O3" value="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBV Temporary Interrupted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBV Permanently Interrupted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Erythropotin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAA Permanently Discontinued</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peg-IFN a-2a Dose Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Other Action Done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1"/>
                    <measurement group_id="O2" value="22.2"/>
                    <measurement group_id="O3" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="4.8"/>
                    <measurement group_id="O3" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had SVR at Week 24 With Dose Modifications</title>
        <description>Participants with dose modifications who had achieved SVR at Week 24 were reported. Data was collected for all participants who had dose modification of Peginterferon alfa-2a, Ribavirin or Telaprevir/boceprevir in any of the treatment regimen during the study.</description>
        <time_frame>Week 24</time_frame>
        <population>mTRT population: includes all participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; the participants' treatment documentation was sufficient for assignment to treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants who had dual or triple therapy as part of their drug regimen at the discretion of the investigator in accordance with the local prescribing information at the time of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had SVR at Week 24 With Dose Modifications</title>
          <description>Participants with dose modifications who had achieved SVR at Week 24 were reported. Data was collected for all participants who had dose modification of Peginterferon alfa-2a, Ribavirin or Telaprevir/boceprevir in any of the treatment regimen during the study.</description>
          <population>mTRT population: includes all participants who had an HCV-RNA result ≥50 IU/mL at their last measurement prior to commencing CHC therapy; had received one of the study's combination therapies; the participants' treatment documentation was sufficient for assignment to treatment groups.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="935"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peginterferon alfa-2a</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ribavirin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telaprevir/boceprevir</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="516"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Correlation with dose modification for Peginterferon alfa-2a.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0463</p_value>
            <method>Chi-squared</method>
            <method_desc>The p-value from chi-square is the difference between SVR achieved (yes/no) and dose modifications.</method_desc>
            <param_type>phi-coefficient</param_type>
            <param_value>-0.0835</param_value>
            <estimate_desc>phi-coefficient is a measure of the degree of association between two binary variables</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Correlation with dose modification for Ribavirin.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2052</p_value>
            <method>Chi-squared</method>
            <method_desc>The p-value from chi-square is the difference between SVR achieved (yes/no) and dose modifications.</method_desc>
            <param_type>phi-coefficient</param_type>
            <param_value>0.0666</param_value>
            <estimate_desc>phi-coefficient is a measure of the degree of association between two binary variables.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Correlation with dose modification for Telaprevir/boceprevir.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0033</p_value>
            <method>Fisher Exact</method>
            <method_desc>The p-value from chi-square is the difference between SVR achieved (yes/no) and dose modifications.</method_desc>
            <param_type>phi-coefficient</param_type>
            <param_value>-0.1672</param_value>
            <estimate_desc>phi-coefficient is a measure of the degree of association between two binary variables.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 48</time_frame>
      <desc>The Safety Analysis population was defined to include only participants who had received at least one dose of a peginterferon alfa-2a plus ribavirin, or a peginterferon alfa-2a plus ribavirin plus telaprevir/boceprevir and had at least one post-baseline safety assessment. Safety analysis included 2 additional participants in arm 'Peginterferon Alfa-2a + Ribavirin + Telaprevir'. The safety parameters were analyzed by the treatment actually received by the participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Peginterferon Alfa-2a + Ribavirin</title>
          <description>Dual Therapy. Dosing and treatment duration of the dual therapy (Peginterferon Alfa-2a + Ribavirin) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
        </group>
        <group group_id="E2">
          <title>Peginterferon Alfa-2a + Ribavirin +Telaprevir</title>
          <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin + Teleprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
        </group>
        <group group_id="E3">
          <title>Peginterferon Alfa-2a + Ribavirin + Boceprevir</title>
          <description>Triple Therapy. Dosing and treatment duration of the triple therapy (Peginterferon Alfa-2a + Ribavirin +Boceprevir) were at the discretion of the Investigator in accordance with the current local prescribing information.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Haemolytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing Impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Face Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cryptococcal Fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diabetic Foot Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Salmonella Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma Pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Calculus Urethal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Renal Stone Removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Vena Cava Filter Removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="208" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="338" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="161" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Anorectal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Sleep Disorder</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>Genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

